SECsense Logo

Halozyme Therapeutics 8-K Report: Key Updates & Insights from January 8, 2025

$HALO
Form 8-K
Filed on: 2025-01-08
Source
Halozyme Therapeutics 8-K Report: Key Updates & Insights from January 8, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Company Information:
  • Name: Halozyme Therapeutics, Inc.
  • CIK (Central Index Key): 0001159036
  • SEC File Number: 001-32335
  • State of Incorporation: Delaware (DE)
  • Federal Tax Identification Number: 88-0488686
  • Address: 12390 El Camino Real, San Diego, CA 92130
  • Phone Number: 858-794-8889
  1. Stock Information:
  • Type of Security: Common Stock
  • Par Value: $0.001
  • Ticker Symbol: HALO
  • Market: NASDAQ
  1. Filing Details:
  • Filing Type: 8-K (a report of unscheduled material events or corporate changes)
  • Filing Date: January 8, 2025
  • Period Covered by Filing: January 8, 2025 (the report appears to cover a single day).
  1. XML Metadata:
  • The document is structured in XBRL (eXtensible Business Reporting Language), which is commonly used for financial reporting and allows for easier data extraction and analysis.
  1. Schema Reference:
  • There is a reference to a specific XSD schema file (halo-20250108.xsd), which may define the structure and elements used in the filing.

Insights:

  • The filing indicates that Halozyme Therapeutics is actively communicating important events to the SEC, which is critical for transparency and investor relations.
  • The specific mention of the 8-K filing suggests that there may have been a significant event or change that warranted this immediate disclosure.
  • The company is publicly traded on NASDAQ, indicating it has met the requirements for listing and compliance with SEC regulations.

This information is essential for investors, analysts, and stakeholders who are monitoring the company’s performance and any potential impacts on its stock value or operations.